The scope for FMD in Belgium is defined as:
For products referred to in art. 54(o) of Directive 2001/83/EC, ie, medicinal products other than radiopharmaceuticals (referred to in art. 54a(1))
- a) All products on prescription
- b) Reimbursable products that are bearing a Unique Bar Code (UBC) today
- c) Products on annex II of the D.R. (black list)
- d) With the exclusion of any product from a) or b) that appears on annex I of the D.R. (white list)
Further clarification on b):
Not all reimbursable products are requested to have a UBC today.
– Analgesics that are reimbursed for Chronicle Pain do not have a UBC and are not in scope for FMD
– Contraceptives that are not reimbursed but for which there is a specific compensation for women under the age of 21, have no UBC and are not in scope
(Note: contraceptives with the ‘standard’ Cx reimbursement are in scope)
– Chapter III medicines: more precisely, perfusions delivered through the public pharmacy have a UBC today, but will no longer need to have a UBC in the future and will not be in scope
Laxatives and calcium supplements (associated or not with vitamin D), that need to be registered by the pharmacist, do not have a UBC and are also not in scope.